There are relevant dimensions from a gender perspective related to therapeuticeffort. To illustrate and discuss possible gender bias related tomedicines, through the consumption analysis in women, the prescriptionof biological drugs according to sex, the potential gender inequalityin adverse drug reactions, and research with clinical trials, as well asthe decisions of international institutions in the marketing of medicinalproducts.There is greater tendency to prescribe pain relievers, regardless of pain,and drugs for low intensity depressive symptoms in women than in men.The opposite occurs in the prescription of statins and adequate doses,and with the greater probability of prescribing anti-tumor necrosis factor inmen than in women with ankylosing spondylitis, despite a similar diseaseburden. Adverse drug reactions are observed more frequently in womenthan in men, where determinants such as body weight are having littleinfluence on the dosage. It is currently scarcely considered in the prescriptionthat women have differences in the activity of cytochrome CYPP450enzymes, which can affect the liver's metabolism rate. There are evenimmunological, genetic and epigenetic effects (due to heredity and unevengene dosing located in the X and Y chromosomes) that can influence these differences by sex. Finally, through cases of hormonal therapy clinical trials, a drug for women's inhibited sexual desire and a contraceptive for men, gender bias and stereotypes are shown to influence a potential generation of inequalities, especially in adverse drug reactions to the detriment of women. In conclusion, health professionals frequently attribute physical symptoms to women's emotionality, influencing their greater prescription of symptomatic drugs. Whether the same reason influences the lower prescription of therapeutic drugs in women than in men should be analyzed. There are biological determinants to consider due to their influence on a greater pharmacological toxicity in women. Clinical trials should improve according to the gender recommendations by the Food and Drugs Administration.